Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management

This publication has 102 references indexed in Scilit:

• Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner
  The American Journal of Cardiology, 2004
• The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease
  American Heart Journal, 2003
• Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events
  Circulation, 2003
• Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease
  Nature Genetics, 2003
• The genetic basis of variability in drug responses
  Nature Reviews Drug Discovery, 2002
• Initial sequencing and analysis of the human genome
  Nature, 2001
• Assessing the cost-effectiveness of pharmacogenomics
  AAPS PharmSci, 2000
• Power of Linkage versus Association Analysis of Quantitative Traits, by Use of Variance-Components Models, for Sibship Data
  American Journal of Human Genetics, 2000
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Association of Specific LDL Receptor Gene Mutations With Differential Plasma Lipoprotein Response to Simvastatin in Young French Canadians With Heterozygous Familial Hypercholesterolemia
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1998